The COCOON Protocol and COPERNICUS Study Design for Dermatologic Toxicity Management in EGFR-Mutated NSCLC

Dr. Riess presents the COCOON trial data, which evaluated a standardized prophylactic regimen for dermatologic adverse event management with amivantamab-lazertinib in patients with EGFR-mutated NSCLC. The COCOON protocol reduced grade 2 or higher toxicity from 75% to 42% (odds ratio 0.24; statistically significant), with the largest reductions in face and body rash and scalp toxicity. NCCN guidelines now recommend this prophylactic approach. COPERNICUS has incorporated the COCOON dermatologic management protocol prospectively across both cohorts, alongside the subcutaneous amivantamab formulation and an every-4-week dosing schedule.

Dr. Fidler describes how the COPERNICUS design reflects the field's evolution in operationalizing dermatologic toxicity management for amivantamab-lazertinib. Key practical elements include subcutaneous amivantamab administration, which substantially reduces infusion-related reactions from approximately 66% to 13% compared with intravenous formulation; dexamethasone premedication for the initial infusion; and the every-4-week dosing interval, which improves patient convenience without evidence of increased toxicity from dose interval extension. She notes that unlike her experience with immune checkpoint inhibitors, where some patients have difficulty tolerating extended dosing intervals, no increased toxicity has been observed with the every-4-week amivantamab schedule to date.

Dr. Fidler highlights the comprehensive supportive care regimen accompanying amivantamab-lazertinib as essential to treatment continuity: prophylactic anticoagulation for venous thromboembolism risk during the first 4 months, oral antibiotic prophylaxis with doxycycline, twice-daily topical applications including ceramide-based moisturizer, nail bed protection, and scalp care. She notes that these components collectively reduce grade 2 or higher dermatologic events substantially and are a prerequisite to keeping patients on therapy long enough to derive clinical benefit.